Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows From Operating Activities
Net income (loss)	$ 50,847	$ (8,246)
Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities:
Stock-based compensation	28,161	22,283
Deferred taxes	11,881	(4,383)
Depreciation and amortization	68,804	45,131
Unrealized gain on investment in equity securities	(2,551)	(8,298)
Non-cash operating lease expense	1,204	1,134
Non-cash interest	1,005	319
Contingent consideration fair value adjustment	(25,285)	1,274
Loss (gain) on disposal of assets	295	(5,347)
Loss on debt extinguishment	0	7,468
Amortization of inventory step up	0	3,224
Asset impairment charges	767	0
Changes in operating assets and liabilities:
Accounts receivable, net	(30,674)	4,426
Inventories	(9,693)	(20,612)
Prepaid expenses and other assets	(564)	3,822
Accounts payable	22,391	7,300
Accrued royalties	28,621	7,171
Income taxes	(16,003)	(14,268)
Accrued government rebates	18,318	(1,475)
Returned goods reserve	10,731	4,296
Accrued expenses, accrued compensation, and other	(3,397)	2,938
Net Cash and Cash Equivalents Provided by Operating Activities	154,858	48,157
Cash Flows From Investing Activities
Acquisition of Alimera, net of cash acquired	0	(393,079)
Acquisition of product rights, intangible assets, and other related assets	(20,327)	(631)
Acquisition of property and equipment, net	(12,591)	(13,842)
Proceeds from the sale of building	0	13,514
Net Cash and Cash Equivalents Used in Investing Activities	(32,918)	(394,038)
Cash Flows From Financing Activities
Proceeds from convertible notes	0	316,250
Proceeds from term loan	0	325,000
Purchase of capped call transaction	0	(40,575)
Repayment on borrowings under credit agreement	0	(292,500)
Debt issuance costs	0	(15,376)
Principal payments on borrowings	(6,093)	(1,500)
Series A convertible preferred stock dividends paid	(1,157)	(1,219)
Proceeds from stock option exercises and ESPP purchases	13,566	4,788
Treasury stock purchases for restricted stock vests	(11,598)	(10,641)
Payments on contingent consideration	(26)	(12,500)
Payment of accrued licensor payments	0	(1,875)
Net Cash and Cash Equivalents (Used in) Provided by Financing Activities	(5,308)	269,852
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	1,120	(75)
Net Change in Cash, Cash Equivalents, and Restricted Cash	117,752	(76,104)
Cash, cash equivalents, and restricted cash, beginning of period	144,894	221,121
Cash, cash equivalents, and restricted cash end of period	262,646	145,017
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Cash and cash equivalents	262,610	144,982
Restricted cash	36	35
Total cash, cash equivalents, and restricted cash	262,646	145,017
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	22,318	19,232
Cash paid for income taxes	16,613	17,214
Supplemental non-cash investing and financing activities:
Conversion of convertible preferred stock into common stock	24,850	0
Right of use assets obtained in exchange for new operating lease liabilities	5,244	0
Property and equipment purchased and included in accounts payable	1,029	635
Purchase consideration for Alimera Acquisition	0	(16,523)
Accrued deferred financing costs	$ 0	$ (1,976)